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 CURRENTOPINION Mitochondria as therapeutic targets in acute
kidney injury
Andrew M. Hall and Claus D. Schuh
Purpose of review
Mitochondria are complex intracellular organelles with a variety of important functions. The kidney tubule
is densely packed with mitochondria, and mitochondrial dysfunction is thought to be central to the
pathogenesis of acute kidney injury (AKI). Mitochondria therefore represent potential targets for novel
therapeutic interventions in AKI.
Recent findings
Several mitochondrial targeted approaches have shown promise in recent preclinical studies of AKI,
including measures to: reduce oxidative stress within mitochondria; prevent mitochondrial fission and
activation of cell death pathways; enhance recycling of damaged mitochondria via autophagy and
mitophagy; and accelerate mitochondrial biogenesis postinsult.
Summary
Recent studies show that it is now eminently feasible to pharmacologically manipulate various key
aspects of mitochondrial biology in the kidney, and this has much potential for the future treatment of
AKI. However, significant hurdles will have to be overcome in the translational pathway for these
strategies to successfully migrate to the clinic.
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INTRODUCTION
The renal tubule, and in particular the proximal
tubule, is densely packed with mitochondria,
which exist primarily to generate sufficient
quantities of ATP, via oxidative phosphorylation
(OXPHOS), to power the huge amounts of solute
transport performed every day in the kidney.
The importance of mitochondria in the proximal
tubule is illustrated by the fact that renal Fanconi
syndrome is the most common kidney phenotype
in children with genetic mitochondrial diseases
[1,2]. Moreover, mitochondrial defects are impli-
cated in the pathogenesis of a wide range of kidney
diseases, including diabetic nephropathy and
certain types of nephrotic syndrome [3]. However,
most attention to date has focused on the role
of mitochondria in acute kidney injury (AKI),
in which all of the major causes in humans –
ischemia-reperfusion injury (IRI), drug toxicity,
and sepsis – are thought to induce mitochondrial
damage in the proximal tubule.
AKI is associated with significant morbidity
and mortality, and thus represents a major public
health burden. The hitherto fruitless quest for
effective treatments for AKI is now increasingly
moving into the realm of the mitochondrion,
driven by a potent cocktail of factors, including
an explosion of new knowledge concerning basic
mitochondrial biology, the increasing recognition
of their importance in the pathogenesis, and the
development of drugs that can specifically target
mitochondria. In this article, the potential roles
of some recently studied mitochondrial therapies
in AKI will be discussed. Ultimately, the key ques-
tion is, can any of these effectively prevent or reverse
AKI in humans? Only time will tell, but some
important issues to consider in the meantime will
be discussed in the final section.
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MITOCHONDRIA IN THE KIDNEY TUBULE
Mitochondria are complex organelles present in
almost all eukaryote cells, and are instantly recog-
nizable by their textbook appearance with a double
membrane and numerous cristae formed by infold-
ings of the inner membrane. They are thought
to be descended from a bacterial ancestor, and
provide a huge evolutionary advantage for their
host cells by virtue of the fact that they perform
aerobic respiration, which generates significantly
more ATP per fuel molecule than anaerobic proc-
esses. Put simply, withoutmitochondria the energy
needs of the kidney could not be met. In addition,
mitochondria have a range of other important
functions, including biosynthesis of macromol-
ecules and modulation of intracellular Ca2þ
signals. Furthermore, they are probably a major
source of reactive oxygen species (ROS) production
and also have a key role in the activation of cell
death pathways (apoptosis and necrosis). It follows
from this that mitochondrial dysfunction can
potentially be harmful to host cells in a number
of different ways, many of which have yet to be
fully elucidated [4].
Mitochondria are highly dynamic organelles,
capable of moving, fusing, and dividing. Total mito-
chondrial mass is determined by the balance
between the rate of breakdown and removal – via
a dedicated form of autophagy termed mitophagy –
and by the rate of generation of new organelles
(mitochondrial biogenesis). It is becoming increas-
ingly clear that disorders in mitochondrial dynam-
ics, recycling, and biogenesis can all cause or worsen
disease states in humans [5], leading to the concept
that these processes could represent targets for
therapeutic interventions.
MITOCHONDRIA IN ACUTE KIDNEY
INJURY
For reasons that remain incompletely explained,
the proximal tubule lacks the capacity to perform
anaerobic glycolysis [6]. As such, it is exquisitely
sensitive to aerobic insults, such as IRI, and cellular
ATP levels plummet within seconds of oxygen depri-
vation [7]. Increasing evidence suggests that mito-
chondria are also damaged in septic AKI, but it
remains unclear whether this is secondary to a lack
of oxygen delivery (the classical paradigm) or rather
direct toxicity induced by the inflammatory milieu,
although opinion seems to coalescing more around
the latter concept [8]. Mitochondria in the proximal
tubule are also damaged by therapeutic drugs that
frequently cause AKI, such as ifosfamide, cisplatin,
tenofovir, and gentamicin [9]. Moreover, a very
recent study suggests that elevated urinary mito-
chondrial DNA (mtDNA) predicts the development
of AKI in humans undergoing cardiac surgery [10].
The realization thatmitochondria play a central role
in AKI has stimulated the search for new therapies
that can target these complex and fascinating
organelles.
MITOCHONDRIAL-TARGETED THERAPIES
The overall aims of mitochondrial-targeted thera-
pies in AKI are essentially to achieve one of three
things: to limit harm tomitochondria andminimize
the downstream consequences for the cell; to
enhance recycling of damaged mitochondria; or
to accelerate recovery of normal mitochondrial
mass and function postinsult. More specifically,
they can currently be classified as targeting one of
four distinct processes: mitochondrial ROS gener-
ation and oxidative stress; mitochondrial fission
and activation of cell death pathways; mitochon-
drial breakdown via autophagy/mitophagy; and
mitochondrial biogenesis. In the following sections,
consideration will be given to the respective merits
of each of these approaches. As this article is focused
on strategies currently in vogue, older targets will
not be discussed, such as inhibitors of themitochon-
drial permeability transition pore, which have been
covered in depth elsewhere [11].
Mitochondrial-targeted antioxidants
Mitochondria are thought to be amajor intracellular
source of ROS (produced as a byproduct of
OXPHOS), and oxidative stress has been widely
implicated in many disease processes. In fact, it
now represents a considerable challenge to identify
any where it has not. Conversely, clinical trials with
nonspecific antioxidants have proven to be a major
KEY POINTS
 Mitochondria are complex dynamic organelles, and
mitochondrial dysfunction is central to the pathogenesis
of AKI.
 Several mitochondrial targeted therapies have recently
been developed and tested in preclinical models
of AKI.
 Mitochondrial-specific antioxidants and inhibitors of
mitochondrial fission are protective, whereas stimulation
of mitochondrial biogenesis can enhance
recovery postinsult.
 The role of autophagy/mitophagy in AKI remains
controversial, with conflicting results from
different studies.
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disappointment. This apparent paradox naturally
leads to two possible conclusions. First, ROS may
not actually be as important as previously thought.
Alternatively, more selectively targeted antioxi-
dants might be required to achieve a therapeutic
effect. The latter argument is supported by the
emerging concept that nonmitochondrial ROS
can have important physiological roles, such as
the regulation of solute transport in the kidney
[12]. Mitochondrial ROS production is thought to
increase when normal OXPHOS is compromised
(e.g. in IRI), so antioxidants targeted to mitochon-
dria could be of benefit, to limit oxidative stress and
damage specifically within these organelles.
Three classes of mitochondrial-targeted antiox-
idants have been developed in recent years – SS-
peptides, MitoQ, and plastoquinone analogues
(SkQ1/SkQR1) – all of which work on a similar
principle. As lipophilic cations, they selectively
accumulate into the mitochondrial matrix at very
high concentrations, utilizing the voltage gradient
across the mitochondrial inner membrane created
by theOXPHOS complexes (the SS peptidesmay also
interact with cardiolipin, a major constituent of the
mitochondrial inner membrane [13]). All three
classes of these agents have shown evidence of
benefit in preclinical models of AKI and appear to
have satisfactory safety profiles.
Discovered by serendipity [14], the SS peptides
arguably show the greatest promise for AKI at
present. In a series of studies in rodent models by
Szeto et al. [13,15
&&
], it has been shown that two
agents in this class (SS-20 and SS-31) offer significant
protection in AKI because of IRI, with striking
positive effects on mitochondrial morphology and
function, cell polarity, and overall kidney function.
SS-31 (marketed as Bendavia) has also shown
evidence of benefit in a larger animal model
(renovascular disease in pigs) [16], and the effects
in human AKI are now being investigated. Mean-
while, MitoQ, an analogue of the OXPHOS
component ubiquinone (CoQ10), has been studied
in a multitude of different disease processes in
different organs, including in humans [17]. Regard-
ing the kidney, it has recently been shown to have
beneficial effects in AKI induced by IRI [18] and
cisplatin [19]. The plastoquinone analogues also
seem to be protective in preclinical AKI models,
including IRI, rhabdomyolysis, and gentamicin
toxicity [20,21]. One potential limitation of all of
these agents is that they have to be given before
the insult, so their clinical usage would effectively
be confined to scenarios where AKI is predictable.
However, this is also the case for many other
nonmitochondrial therapies currently in develop-
ment. Moreover, the fact that such structurally
heterogeneous compounds have all shown benefit
in various models in different research groups
suggests that targeting mitochondrial ROS pro-
duction is a strategy worth pursuing (albeit with
the caveats discussed in the final section).
Another recently identified method to lower
mitochondrial ROS production involves the signal-
ingmolecule stanniocalcin-1 (STC1), which is highly
expressed in the kidney [22]. STC1 is a stress protein
that responds to stimuli such as hypoxia, and traffics
to the mitochondrial membrane, where it increases
the expression of uncoupling proteins, which, in
turn, may reduce the rate of ROS production by
the mitochondrial OXPHOS complexes (possibly
by lowering the potential across the mitochondrial
inner membrane, although this mechanism remains
controversial). Transgenic overexpression of STC1
in mice provides protection against IRI-induced
AKI [22], and a very recent follow up study has
suggested that it may also activate AMP-activated
kinase (AMPK) [23
&&
], a crucial metabolic sensor that
regulates mitochondrial function (see the section
below on mitochondrial biogenesis). Meanwhile,
another study hot off the press has suggested that
mitochonic acid, a derivative of the plant hormone
indole-3-acetic acid, also lowers mitochondrial ROS
production, and shows evidence of benefit in AKI
because of IRI [24
&&
]. Mitochonic acid is thought to
target the inner mitochondrial membrane protein
mitofilin, and may also work by maintaining
the normal structure of mitochondrial cristae and
promoting ATP production.
Mitochondrial dynamics
Mitochondria are highly dynamic organelles,
capable of fusing and dividing with each other, to
exchange genetic and other information. Accord-
ingly, mitochondria are increasingly viewed as
existing within complex interconnected networks,
rather than as isolated entities. In the last few years,
several key players in mitochondrial fusion/fission
have been identified, including the profusion
proteins mitofusin 1 and 2 (MFN 1 and 2) and
OPA1, and the profission protein DRP1 [25]. It has
also become clear that genetic mutations in fission/
fusion proteins can cause diseases in humans [5],
and that mitochondrial fission is probably an
important step in the release of proapoptotic factors,
such as cytochrome c, from mitochondria into the
cytosol [25]. There is, therefore, increasing interest
in targetingmitochondrial dynamics pharmacologi-
cally in AKI.
In numerous previous studies, including from
our own group, it has been demonstrated that
normally elongated mitochondria in the proximal
Mitochondria and acute kidney injury Hall and Schuh
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tubule rapidly fragment in response to insults such
as IRI and cisplatin (Fig. 1) [26]. In an elegant
series of experiments, Brooks et al. [27] demon-
strated in both cell and mouse models that DRP1 is
rapidly recruited to fragmented mitochondria in
the proximal tubule. They reported that inhibition
of DRP1 activity, using either genetic or pharma-
cological approaches, was protective against mito-
chondrial fragmentation, initiation of apoptosis,
and overall kidney damage. The DRP1 inhibitor
used (Mdivi-1) has also now been shown to have
beneficial effects in various other organ systems
[28], and could represent a potential new therapy
in human AKI.
Further evidence for the importance of mito-
chondrial dynamics was provided by a very recent
study that investigated the role of the profusion
protein MFN2 [29
&&
]. In this work, a mouse with a
conditional knockout of MFN2 in renal tubules was
used, as embryonic deficiency is lethal. As expected,
mitochondria within the proximal tubules of these
animals are punctate and fragmented, consistent
with a greater tendency towards mitochondrial fis-
sion. However, contrary to expectations, the MFN2-
deficient animals showed greater protection against
IRI-induced AKI, compared to wild types. The expla-
nation for this counter-intuitive result is not clear,
but might relate to an increased capacity for tubular
cell proliferation postinsult in the MFN2-deficient
mice. These intriguing results further underline that
mitochondrial dynamics are important in the
pathogenesis of AKI, but also suggest that the
relationship between mitochondrial morphology
and outcome might not be so simple as previously
thought.
Autophagy and mitophagy
Damaged mitochondria within cells are identified
and removed by a process of selective autophagy
termed mitophagy, whereby they are engulfed by
auto-phagosomes, which then subsequently fuse
with lysosomes, within which degradation of
contents takes place. The turnover of mitochondria
in the proximal tubule is thought to be quite high
(estimated half-life of 2 weeks [30]), and inhibition
of autophagy leads to the accumulation of damaged
mitochondria and proximal tubule dysfunction
[31]. Previous studies have shown that autophagy
is activated in tubular cells in AKI, and pharmaco-
logical enhancement of this process could in theory
minimize cellular stress and accelerate recovery.
Support for this concept was provided by studies
showing that genetic or pharmacological inhibition
of autophagy worsened outcome in response to
insults such as cisplatin and IRI, whereas activation
with the mTOR inhibitor rapamycin was protective
[31–33]. However, other studies have reported very
different findings, and the role of autophagy in AKI
thus remains hotly debated [34]. A full discussion of
this topic is beyond the scope of this article, but
plausible explanations for conflicting results
include the dynamic nature of the autophagic proc-
ess [35], cross-talk with cell death pathways, and a
paucity of specific activators, inhibitors andmarkers
of mitophagy [34]. Resolving these issues will
(a) (b)
FIGURE 1. Mitochondrial damage in acute kidney injury. (a) Kidney proximal tubules contain a high density of mitochondria,
which have a characteristic elongated appearance and basolateral distribution. (b) Example image acquired 48h post
cisplatin exposure, showing damaged and fragmented mitochondria in proximal tubules. Images were acquired in live
anesthetized mice using intravital multiphoton microscopy and the fluorescent mitochondrial-specific probe
tetramethylrhodamine methyl ester (TMRM). Scale bar¼10mm.
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therefore be necessary to enable the realistic
evaluation of mitophagy as a target in AKI.
Mitochondrial biogenesis
AKI in humans is typically characterized by tubular
cell damage rather than cell death [36]. Therefore,
although some degree of cell proliferation and
replenishment undoubtedly takes place, the prin-
ciple component of recovery postinsult is probably
the reestablishment of normal structure, function,
and polarity in surviving proximal tubule cells.
As part of this process, damaged mitochondria
removed via mitophagy need to be replaced by
newly generated organelles. Much has been learnt
in the last few years concerning the key molecules
that drive mitochondrial biogenesis within cells,
and pharmacological enhancement of this process
might accelerate recovery in AKI [37,38].
Peroxisome proliferator-activated receptor-g
coactivator-1a (PGC-1a) is a transcriptional coacti-
vator that has been identified as a master regulator
of mitochondrial biogenesis. The expression of
PGC-1a in the kidney cortex has been shown to
decline in parallel with renal function in a model of
septic AKI, and then increase in the recovery phase,
whenmitochondrial biogenesis should be occurring
[39]. Moreover, mice with a genetic defect of PGC-
1a in the proximal tubule were more susceptible
to injury, whereas in-vitro cell experiments suggest
that overexpression of PGC-1a postinsult can
enhance recovery [40]. Peroxisome proliferator-acti-
vated receptor-g activators act upstream of PGC-1a
and were previously used in the treatment of dia-
betes mellitus. Experimentally, these agents have
shown beneficial effects in AKI because of insults
including IRI, cisplatin and tenofovir [41–43]. How-
ever, they are no longer in widespread clinical usage
because of adverse side effects. Another upstream
activator of PGC-1a is AMPK, which acts as a crucial
metabolic switch, effectively upregulating cellular
metabolism in response to a fall in ATP level, and
pharmacological activation of AMPK has been
shown to be protective in AKI because of IRI [44].
Moreover, as mentioned earlier, very recent work
suggests that the extracellular signaling protein
STC1 also acts via the AMPK pathway [23
&&
].
Attention in the mitochondrial biogenesis
field has also focused recently on sirtuins, which
are protein deacetylases that have key roles in
regulating cellular metabolism, mainly in response
to changes in NADH/NADþ ratio. The sirtuin 1
(SIRT1) activator SRT1720 stimulates mitochondrial
biogenesis via the PGC-1a pathway, and has been
shown to enhance mitochondrial recovery and
tubular function following IRI [45].Meanwhile, very
recent work suggests that SIRT3 (which is mainly
localized in mitochondria) is downregulated in
cisplatin-induced AKI, and that SIRT3-deficient
mice are more susceptible to injury [46
&&
]. Upstream
activation of AMPK conferred mitochondrial
protection in wild-type but not SIRT3-deficient
mice, suggesting that AMPK acts via SIRT3. There
are currently no known specific activators of SIRT3,
so the search is now on for such agents.
Finally, Schnellmann et al. have used unbiased
high-throughput screening approaches to search for
novel activators of mitochondrial biogenesis, and
have identified the b2-adrenergic receptor agonist
formoterol as a promising candidate. In their most
recent work, they have demonstrated that formo-
terol enhances the restoration of mitochondrial
proteins and function in the kidney post-IRI, and
also completely restores kidney function, suggesting
that it could represent a promising new treatment
for AKI [47
&&
].
CHALLENGES AHEAD
In the preceding sections, an attempt has beenmade
to succinctly describe novel strategies currently
being explored to target mitochondria in AKI (sum-
marized in Fig. 2). In the final part, some consider-
ationwill be given to the challenges that lie ahead in
migrating this exciting mass of preclinical data into
effective treatments. First, some historical context is
required; in the last few decades, the battlefield of
AKI research has become strewn with the corpses of
initially promising yet ultimately ineffective treat-
ment strategies, the latest high-profile victim being
ischemic preconditioning [48]. There are a variety of
now widely recognized reasons for this, which have
been covered in detail in other recent articles
[49
&
,50]. In summary, they include issues such as
inadequacy of experimental models, publication
bias, lack of appropriate biomarkers, preexisting
comorbidities, and an overobsession with finding
a single ‘silver bullet’ targeting a solitary pathway
(rather than adopting a more sophisticated multi-
level intervention strategy). Moreover, there may be
significant species differences in how the kidney
responds to insults; for example, a recent study
has suggested that IRI induces much less severe
structural changes in proximal tubule cells in
humans than in rodents [51].
In addition to these general points, several
issues specific to mitochondrial therapies require
consideration. For example, in addition to a patho-
physiological role in promoting oxidative stress,
mitochondrial generated ROS might also have an
important signaling role in providing feedback to
the nucleus, and thus initiating an appropriate cell
Mitochondria and acute kidney injury Hall and Schuh
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stress response, including expression of transcrip-
tion factors that regulate mitochondrial biogenesis
[52]. Moreover, although antioxidants can be
designed to accumulate within mitochondria, for
most other drugs specifically targeting and access-
ing these organelles represents a huge pharmaco-
logical challenge. Furthermore, despite the fact that
mitophagy could be a key component of the cellular
response to AKI, it remains unclear whether we
should be trying to help or hinder this process.
Finally, although there are now several strategies
available to enhance mitochondrial biogenesis
postinsult, there are theoretical risks in doing so.
For example, increased proliferation of damaged
and incompletely recovered mitochondria might
increase oxidative stress within cells.
Probably the biggest hindrance to date in mito-
chondrial medicine has been a lack of techniques
to study key aspects of mitochondrial physiology
in living animals. Accordingly, much of what mito-
chondria actually do in their native environment
remains a mystery. For example, for all the in vitro
studies implicating a role for ROS in kidney diseases,
we have absolutely no idea how much ROS are
actually produced in tubular cells in vivo. It could
be argued, therefore, that we have no convincing
rationale as yet to trial mitochondrial-targeted
antioxidants in humans; highly effective in preclin-
ical studies they may be, but then so was ischemic
preconditioning. Serendipity aside, successful
implementation of mitochondrial therapies to
the kidney field will be ultimately be dependent
on developing technologies that allow detailed
and comprehensive real-time assessment of mito-
chondria in vivo, and how exactly these organelles
are affected by disease causing insults and putative
treatments.
CONCLUSION
Mitochondria are central to the pathogenesis of AKI,
so when searching for new therapeutic targets
it makes sense to focus on them. It is now demon-
stratively possible to manipulate various key aspects
of mitochondrial physiology in vivo – including
redox state, dynamics, recycling, and regeneration
– and recent studies suggest that doing so could
be beneficial in AKI. Additional gains might also
be made by combining more than one of these
strategies. However, many major hurdles lie ahead
in the translational pathway, and overcoming these
will require a critical and creative appraisal of what
has gone wrong in the past in AKI research and what
needs to change. To properly understand what hap-
pens to mitochondria in AKI, and which interven-
tions are really effective, we may need to prioritize
the development of better technology over perform-
ing more clinical trials. For the very definition of
stupidity is to repeat the same thing over and again,
yet somehow expect a different result.
1. Mitochondrial specific
anti‐oxidants
(e.g. SS-peptides, MitoQ)
↑ROS
2. Inhibitors of
mitochondrial
fission
(e.g.
Mdivi-1)
3. Enhancement of
mitophagy
(e.g. mTOR inhibitors)
4.Stimulation of
mitochondrial biogenesis
(e.g. PGC-1α, AMPK,
Sirtuins, β-agonists)
FIGURE 2. Summary diagram of current experimental strategies to target mitochondria in acute kidney injury.
(1) Mitochondrial-specific antioxidants, such as SS-peptides and MitoQ, accumulate within the mitochondrial matrix and can limit
the increase in reactive oxygen species (ROS) that is thought to occur in acute kidney injury (AKI), thus minimizing oxidative
stress. (2) Inhibition of the pro-fission protein DRP-1 with Mdivi-1 can limit mitochondrial fragmentation and the subsequent
activation of cell death pathways. (3) Damaged mitochondria are removed via mitophagy, whereby they are engulfed by
auto-phagosomes, and enhancement of this process might be beneficial in AKI, but this remains controversial. (4) Stimulation
of mitochondrial biogenesis by various methods can accelerate recovery post AKI. AMPK, AMP-activated kinase; PGC-1a,
peroxisome proliferator-activated receptor-gamma coactivator-1 alpha.
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